UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 190

Sortiert nach

Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4492-4499

2010

Volltextzugriff (PDF)

Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies

Oncoimmunology, 2020-01, Vol.9 (1), p.1751548-1751548

2020

Volltextzugriff (PDF)

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma

Haematologica (Roma), 2013-03, Vol.98 (3), p.357-363

2013

Volltextzugriff (PDF)

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials

Haematologica (Roma), 2010-07, Vol.95 (7), p.1176-1182

2010

Volltextzugriff (PDF)

The adjusted International prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma

Haematologica (Roma), 2007-08, Vol.92 (8), p.1067-1074

2007

Volltextzugriff (PDF)

Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma

Supportive care in cancer, 2018-04, Vol.26 (4), p.1253-1264

2018

Volltextzugriff (PDF)

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis

Journal of clinical oncology, 2014-10, Vol.32 (29), p.3347-3348

2014

Volltextzugriff (PDF)

Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

Annals of hematology, 2013-09, Vol.92 (9), p.1151-1179

2013

Volltextzugriff (PDF)

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

British journal of haematology, 2017-09, Vol.178 (5), p.699-708

2017

Volltextzugriff (PDF)

BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival

Leukemia & lymphoma, 2022-01, Vol.63 (1), p.101-108

2022

Volltextzugriff (PDF)

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

British journal of haematology, 2019-05, Vol.185 (3), p.480-491

2019

Volltextzugriff (PDF)

Intensification treatment based on early FDG‐PET in patients with high‐risk diffuse large B‐cell lymphoma: a phase II GELTAMO trial

British journal of haematology, 2014-11, Vol.167 (3), p.327-336

2014

Volltextzugriff (PDF)

Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14064-e14064

2019

Volltextzugriff (PDF)

Rituximab, interferon‐alfa‐2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH‐PRO‐05 study

British journal of haematology, 2019-07, Vol.186 (1), p.168-170

2019

Volltextzugriff (PDF)

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Blood, 2019-11, Vol.134 (Supplement_1), p.2584-2584

2019

Volltextzugriff (PDF)

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

European journal of haematology, 2007-07, Vol.79 (1), p.32-38

2007

Volltextzugriff (PDF)

Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

Blood, 2014-12, Vol.124 (21), p.5897-5897

2014

Volltextzugriff (PDF)

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin’s Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Blood, 2014-12, Vol.124 (21), p.4465-4465

2014

Volltextzugriff (PDF)

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(175)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(101)
Life Sciences & Biomedicine
(76)
Humans
(66)
Female
(51)
Male
(49)
Middle Aged
(49)
Adult
(45)
Aged
(38)
Hematology
(37)
Treatment Outcome
(26)
Adolescent
(18)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Oncology
(17)
Prognosis
(17)
Disease-Free Survival
(16)
Mars
(16)
Prospective Studies
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Lymphoma
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

The adjusted International prognostic Index and β-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma

Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy

Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

Intensification treatment based on early FDG‐PET in patients with high‐risk diffuse large B‐cell lymphoma: a phase II GELTAMO trial

Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs)

Rituximab, interferon‐alfa‐2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH‐PRO‐05 study

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin’s Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)

Suchergebnisse filtern